Arrowhead Pharmaceuticals (ARWR) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -2,649.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30,461.00 |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | 42,296.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42,296.00 |
| Mar 31, 2026 | -22,450.00 |
| Dec 31, 2025 | 8,282.00 |
| Sep 30, 2025 | 28,269.00 |
| Jun 30, 2025 | -37,127.00 |
| Mar 31, 2025 | 4,287.00 |
| Dec 31, 2024 | -622,571.00 |
| Dec 31, 2023 | -373,234.00 |
| Sep 30, 2023 | -1,636.00 |
| Jun 30, 2023 | -59,074.00 |
| Mar 31, 2023 | 12,745.00 |
| Dec 31, 2022 | -5,089.00 |
| Sep 30, 2022 | -28,776.00 |
| Jun 30, 2022 | -26,602.00 |
| Mar 31, 2022 | -1,243.00 |
| Dec 31, 2021 | -26,235.00 |
| Sep 30, 2021 | -7,025.00 |
| Jun 30, 2021 | 211,921.00 |
| Mar 31, 2021 | 222,644.00 |
| Dec 31, 2020 | 28,065.00 |